Novartis (NVS) Lobbying Data
NVS lobbying summary
Novartis (NVS) has reported $47.2M in federal lobbying spending across 239 Senate LDA filings since 2020. Its most frequent lobbying issues are Health Issues, Medicare/Medicaid, Trade, Taxation. Lobbying firms used include Todd Strategy Group, Brownstein Hyatt Farber Schreck, LLP, Tiber Creek Health Strategies, Inc..
Lobbying spending by year
| Year | Reported spend |
|---|---|
| 2025 | $9.8M |
| 2024 | $7.9M |
| 2023 | $8.3M |
| 2022 | $5.9M |
| 2021 | $8.0M |
| 2020 | $7.5M |
See insider trading for NVS or the Lobbying Heavyweights strategy.
Source: Senate Lobbying Disclosure Act (LD-2) filings. The current year is partial.